Comparative effectiveness of statins in cardiovascular secondary prevention

被引：0
|
作者：
Guillot, Jordan [1 ,2 ]
Moore, Nicholas [1 ,2 ,3 ]
Pariente, Antoine [1 ,2 ]
Bezin, Julien [1 ]
机构：
[1] Univ Bordeaux, Inserm Bordeaux, Populat Hlth Res Ctr, Team Pharmacoepidemiol,UMR 1219, Bordeaux, France
[2] CHU Bordeaux, Pole Sante Publ, Serv Pharmacol Med, Bordeaux, France
[3] Inserm CIC1401, Bordeaux PharmacoEPI, Bordeaux, France
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2018年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
884
引用
收藏
页码：405 / 405
页数：1
相关论文
共 50 条
  • [1] Comparative effectiveness of statins in cardiovascular secondary prevention
    Guillot, J.
    Moore, N.
    Pariente, A.
    Bezin, J.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2018, 32 : 48 - 48
  • [2] ANALYSIS OF CLINICAL AND ECONOMIC EFFECTIVENESS OF STATINS FOR SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE IN KAZAKHSTAN
    Avdeyev, A.
    Makalkina, L.
    Akanov, A.
    Kim, V
    Baidullayeva, D.
    Toktybayeva, A.
    Dyusembayeva, N.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A607 - A608
  • [3] Comparative effectiveness of statins and fibrates for primary prevention of cardiovascular disease and mortality: A cohort study
    Blais, Joseph E.
    Zhao, Jiaxi
    Weng, Stephen
    Yan, Eric Y. F.
    Yan, Vincent K. C.
    Mok, Michael
    Wong, Ian C. K.
    Chan, Esther W.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 107 - 108
  • [4] Statins for Secondary Prevention of Cardiovascular Disease: The Right Dose
    Spector, Reynold
    Snapinn, Steven M.
    [J]. PHARMACOLOGY, 2011, 87 (1-2) : 63 - 69
  • [5] Unhealthy lifestyle, statins and the secondary prevention of cardiovascular disease
    Mascitelli, L.
    Pezzetta, F.
    [J]. INTERNAL MEDICINE JOURNAL, 2007, 37 (06) : 427 - 428
  • [6] SYSTEMATIC REVIEW OF STATINS EFFECTIVENESS IN PREVENTION SECONDARY IN ELDERLY
    Shoshima, A. Y.
    Costa, M. G.
    Tura, B. R.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A914 - A914
  • [7] Comparative effectiveness of statins in secondary prevention among the older people aged 75 years and over
    Arim Kwak
    Jae Hyun Kim
    Cheol Ung Choi
    In-Wha Kim
    Jung Mi Oh
    Kyungim Kim
    [J]. International Journal of Clinical Pharmacy, 2019, 41 : 460 - 469
  • [8] COST-EFFECTIVENESS OF STATINS, EZETIMIBE AND PCSK9 INHIBITOR FOR SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE
    Xiang, Y.
    Du, H.
    Gan, L.
    Li, S.
    Hu, M.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S408 - S408
  • [9] Suboptimal use of statins for secondary cardiovascular prevention: a "planetary" issue
    Bellia, Alfonso
    Della-Morte, David
    Lauro, Davide
    [J]. INTERNAL AND EMERGENCY MEDICINE, 2017, 12 (08) : 1091 - 1092
  • [10] Up to date statins in primary and secondary prevention of cardiovascular diseases
    Puchin'yan, N. F.
    Dovgalevskiy, Ya. P.
    Panina, A. V.
    [J]. RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2012, 8 (04) : 538 - 544
12345